ClinicalTrials.gg
Active, not recruitingNCT05246514DL-05Updated Aug 18, 2026Results posted

A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC

A Phase 2 interventional study of Trastuzumab deruxtecan in HER2-mutant Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung — 5 open to participants now, 9 under way, 2 of them phase 3. trastuzumab deruxtecan · Carcinoma, Non-Small-Cell Lung.

Enrollment
9th of 12
72 · median 167
Started
2022
the only one that year
Phase 2
7 of 12
2 open now
Registered
7th of 12
by date
Lead sponsor
4 of 12
AstraZeneca

Among the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 2, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

5 of the 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing trastuzumab deruxtecan in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.

03

Conditions studied

  • HER2-mutant Non-Small Cell Lung Cancer

Keywords

  • DL05
  • T-DXd
  • HER2-mutant Non-Small Cell Lung Cancer
  • NSCLC
  • Trastuzumab deruxtecan
  • ERBB2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented non-squamous NSCLC.
  • Has from or is refractory to at least one-line of anticancer treatment.
  • Documented exon 19 or 20 mutation from central FFPE tumour tissue testing.
  • WHO or performance status of 0 or 1.
  • Presence of at least one assessed by the investigator based on 1.1.
  • ≥ 50% within 28 days before enrolment.

Exclusion criteria

Exclusion Criteria:

  • Mixed small cell lung cancer, squamous histology NSCLC, and sarcomatoid histology variant NSCLC.
  • interval (QTcF) prolongation to > 470 ms (females) or > 450 ms (males), based on average of the screening triplicate 12-lead .
  • History of (non-infectious) ILD/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Has unresolved toxicities from previous anticancer therapy, defined as toxicities (excluding alopecia) not yet resolved to Grade ≤1 or baseline. Participants with clinically stable chronic Grade 2 toxicity not reasonably expected to be exacerbated by study intervention may be included only after consultation with the AstraZeneca study physician or designee.
  • Has been previously treated with -targeted therapies, except for pan-HER class TKIs or has received prior treatment with an ADC which consists of an exatecan derivative that is a topoisomerase I inhibitor.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    T-DXd arm

    Participants will receive T-DXd as an IV infusion Q3W, on Day 1 of each 3-week cycle.

    Drug: Trastuzumab deruxtecan

Interventions

06

What researchers measure

Primary outcomes

  1. ICR-assessed ORR (Objective Response Rate)

    Confirmed ORR, defined as the percentage of participants with confirmed complete response or partial response, as assessed by independent central review(ICR) based on RECIST 1.1.

    Time frame: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off)

Secondary outcomes

  1. Investigator-assessed ORR (Objective Response Rate)

    Confirmed ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, as determined by the investigator at local site per RECIST 1.1

    Time frame: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off)

  2. ICR-assessed DoR (Duration of Response)

    DoR is time from the initial confirmed response (CR or PR) until documented tumour progression or death from any cause.

    Time frame: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months.

  3. Investigator-assessed DoR (Duration of Response)

    DoR is time from the initial confirmed response (CR or PR) until documented tumour progression or death from any cause.

    Time frame: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months.

  4. ICR-assessed and Investigator-assessed DCR (Disease Control Rate)

    DCR is the percentage of participants who achieved confirmed CR, PR, or SD during study intervention.

    Time frame: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months.

  5. ICR-assessed and Investigator-assessed PFS (Progression-free Survival)

    PFS is the time from date of enrolment until first objective radiographic tumour progression or death from any cause.

    Time frame: Tumour assessments every 6 weeks after enrolment for the first 48 weeks and then every 9 weeks thereafter until date of RECIST 1.1 defined radiological progressive disease or death. Assessed up to 28 months.

  6. OS (Overall Survival)

    OS is the time from date of enrolment until death from any cause.

    Time frame: From date of enrolment until death due to any cause. Assessed up to 28 months.

  7. ICR-assessed CNS-PFS (Central Nervous System Progression-free Survival)

    CNS-PFS is the time from date of enrolment until CNS tumour progression per RECIST 1.1 as assessed by ICR or death due to any cause in the absence of CNS progression.

    Time frame: Tumour assessments every 6 weeks after enrolment for the first 48 weeks and then every 9 weeks thereafter until date of RECIST 1.1 defined CNS tumour progressive disease or death in the absence of CNS progression. Assessed up to 28 months.

  8. Serum Concentrations of T-DXd

    Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd.

    Time frame: 24 weeks from day 1 of cycle 1 to cycle 8

  9. Serum Concentrations of Total Anti-HER2 Antibody

    Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for total anti-HER2 antibody.

    Time frame: 24 weeks from day 1 of cycle 1 to cycle 8

  10. Serum Concentrations of DXd

    Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for DXd.

    Time frame: 24 weeks from day 1 of cycle 1 to cycle 8

07

Results

Posted Dec 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneT-DXd Arm
Started72
Completed29
Not completed43
Withdrew: Death41
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject1

Outcome measures

SecondaryInvestigator-assessed ORR (Objective Response Rate)

Confirmed ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, as determined by the investigator at local site per RECIST 1.1

Time frame:
Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off)
Reported as:
Number · Percentage of participants
Investigator-assessed ORR (Objective Response Rate)
Percentage of participantsT-DXd Arm
Investigator-assessed ORR (Objective Response Rate)59.7 (47.5 to 71.1)
SecondaryICR-assessed DoR (Duration of Response)

DoR is time from the initial confirmed response (CR or PR) until documented tumour progression or death from any cause.

Time frame:
Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months.
Reported as:
Median · Months
ICR-assessed DoR (Duration of Response)
MonthsT-DXd Arm
ICR-assessed DoR (Duration of Response)11.6 (5.8 to NA)
SecondaryInvestigator-assessed DoR (Duration of Response)

DoR is time from the initial confirmed response (CR or PR) until documented tumour progression or death from any cause.

Time frame:
Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months.
Reported as:
Median · Months
Investigator-assessed DoR (Duration of Response)
MonthsT-DXd Arm
Investigator-assessed DoR (Duration of Response)9.4 (7.2 to 13.5)
SecondaryICR-assessed and Investigator-assessed DCR (Disease Control Rate)

DCR is the percentage of participants who achieved confirmed CR, PR, or SD during study intervention.

Time frame:
Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months.
Reported as:
Number · Percentage of participants
ICR-assessed and Investigator-assessed DCR (Disease Control Rate)
Percentage of participantsT-DXd Arm
ICR-assessed91.7 (82.7 to 96.9)
Investigator-assessed93.1 (84.5 to 97.7)
SecondaryICR-assessed and Investigator-assessed PFS (Progression-free Survival)

PFS is the time from date of enrolment until first objective radiographic tumour progression or death from any cause.

Time frame:
Tumour assessments every 6 weeks after enrolment for the first 48 weeks and then every 9 weeks thereafter until date of RECIST 1.1 defined radiological progressive disease or death. Assessed up to 28 months.
Reported as:
Median · Months
ICR-assessed and Investigator-assessed PFS (Progression-free Survival)
MonthsT-DXd Arm
ICR-assessed9.9 (7.1 to 16.5)
Investigator-assessed9.7 (8.1 to 13.4)
SecondaryOS (Overall Survival)

OS is the time from date of enrolment until death from any cause.

Time frame:
From date of enrolment until death due to any cause. Assessed up to 28 months.
Reported as:
Median · Months
OS (Overall Survival)
MonthsT-DXd Arm
OS (Overall Survival)21.0 (17.5 to NA)
SecondaryICR-assessed CNS-PFS (Central Nervous System Progression-free Survival)

CNS-PFS is the time from date of enrolment until CNS tumour progression per RECIST 1.1 as assessed by ICR or death due to any cause in the absence of CNS progression.

Time frame:
Tumour assessments every 6 weeks after enrolment for the first 48 weeks and then every 9 weeks thereafter until date of RECIST 1.1 defined CNS tumour progressive disease or death in the absence of CNS progression. Assessed up to 28 months.
Reported as:
Median · Months
ICR-assessed CNS-PFS (Central Nervous System Progression-free Survival)
MonthsT-DXd Arm
ICR-assessed CNS-PFS (Central Nervous System Progression-free Survival)15.5 (9.9 to NA)
SecondarySerum Concentrations of T-DXd

Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for T-DXd.

Time frame:
24 weeks from day 1 of cycle 1 to cycle 8
Reported as:
Geometric mean · μg/mL
Serum Concentrations of T-DXd
μg/mLT-DXd Arm
Cycle 1 Pre-doseNA ± NA
Cycle 1 End of infusion120.5 ± 18.33
Cycle 1 5 hour post-dose106.1 ± 77.96
Cycle 2 Pre-dose3.072 ± 121.6
Cycle 2 End of infusion117.4 ± 18.79
Cycle 3 Pre-dose5.262 ± 111.2
Cycle 3 End of infusion120.9 ± 17.04
Cycle 4 Pre-dose8.014 ± 60.69
Cycle 4 End of infusion118.4 ± 18.44
Cycle 6 Pre-dose9.024 ± 67.20
Cycle 8 Pre-dose10.39 ± 65.12
SecondarySerum Concentrations of Total Anti-HER2 Antibody

Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for total anti-HER2 antibody.

Time frame:
24 weeks from day 1 of cycle 1 to cycle 8
Reported as:
Geometric mean · ug/mL
Serum Concentrations of Total Anti-HER2 Antibody
ug/mLT-DXd Arm
Cycle 1 Pre-doseNA ± NA
Cycle 1 End of infusion127.5 ± 21.93
Cycle 1 5 hour post-dose118.0 ± 18.85
Cycle 2 Pre-dose2.866 ± 148.7
Cycle 2 End of infusion120.1 ± 39.66
Cycle 3 Pre-dose4.582 ± 126.4
Cycle 3 End of infusion125.9 ± 16.87
Cycle 4 Pre-dose6.974 ± 84.38
Cycle 4 End of infusion121.3 ± 16.80
Cycle 6 Pre-dose8.049 ± 94.39
Cycle 8 Pre-dose9.579 ± 83.64
SecondarySerum Concentrations of DXd

Individual patient data and descriptive statistics will be provided for serum concentration data at each time point for DXd.

Time frame:
24 weeks from day 1 of cycle 1 to cycle 8
Reported as:
Geometric mean · ng/mL
Serum Concentrations of DXd
ng/mLT-DXd Arm
Cycle 1 Pre-doseNA ± NA
Cycle 1 End of infusion5.384 ± 47.55
Cycle 1 5 hour post-dose12.90 ± 69.38
Cycle 2 Pre-dose0.1751 ± 119.4
Cycle 2 End of infusion2.657 ± 70.96
Cycle 3 Pre-dose0.2423 ± 110.6
Cycle 3 End of infusion2.310 ± 50.12
Cycle 4 Pre-dose0.3226 ± 53.71
Cycle 4 End of infusion2.139 ± 51.35
Cycle 6 Pre-dose0.3286 ± 58.35
Cycle 8 Pre-dose0.3749 ± 54.09
PrimaryICR-assessed ORR (Objective Response Rate)

Confirmed ORR, defined as the percentage of participants with confirmed complete response or partial response, as assessed by independent central review(ICR) based on RECIST 1.1.

Time frame:
Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off)
Reported as:
Number · Percentage of participants
ICR-assessed ORR (Objective Response Rate)
Percentage of participantsT-DXd Arm
ICR-assessed ORR (Objective Response Rate)56.9 (44.7 to 68.6)

Adverse events

Collected over From date of informed consent throughout the treatment period and the safety follow-up period (until 40 (+7) days after the last dose of study treatment).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T-DXd41/72 (56.9%)41/72 (56.9%)72/72 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventT-DXd
Platelet count decreasedInvestigations6/72
Covid-19Infections and infestations5/72
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders5/72
PneumonitisRespiratory, thoracic and mediastinal disorders5/72
VomitingGastrointestinal disorders4/72
Covid-19 pneumoniaInfections and infestations4/72
DeathGeneral disorders2/72
AnaemiaBlood and lymphatic system disorders2/72
Herpes zosterInfections and infestations2/72
PneumoniaInfections and infestations2/72
Most frequent other events
Showing 10 of 58
Most frequent other events
EventT-DXd
Platelet count decreasedInvestigations48/72
White blood cell count decreasedInvestigations48/72
Neutrophil count decreasedInvestigations47/72
AnaemiaBlood and lymphatic system disorders46/72
NauseaGastrointestinal disorders43/72
Aspartate aminotransferase increasedInvestigations43/72
Alanine aminotransferase increasedInvestigations36/72
Decreased appetiteMetabolism and nutrition disorders31/72
VomitingGastrointestinal disorders26/72
Covid-19Infections and infestations26/72

Baseline characteristics

Age, Continuous
Age, Continuous(Years)T-DXd Arm
Median57.0 (34 to 76)
Age, Continuous
Age, Continuous(Years)T-DXd Arm
Mean57.4 ± 9.74
Sex: Female, Male
Sex: Female, Male(Participants)T-DXd Arm
Female41
Male31
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)T-DXd Arm
Hispanic or Latino0
Not Hispanic or Latino72
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)T-DXd Arm
American Indian or Alaska Native0
Asian72
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

28 sites
  • Research Site
    Baoding, 071000, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changchun, 130000, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Hangzhou, 310020, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Hefei, 133500, China
  • Research Site
    Hefei, 230601, China
  • Research Site
    Linyi, 276000, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Shandong, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Shenzhen, 518020, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430060, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xiamen, 361003, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhengzhou, 450000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Nov 2024, 27 months.

Results were first posted in Dec 2024, 1 month after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 27 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2022
First posted
Feb 18, 2022
StartActual
Jul 13, 2022
Primary completionActual
Nov 4, 2024
CompletionEst.
Dec 31, 2026
Results first posted
Dec 4, 2024
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05246514
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Jul 13, 2022
Primary completion
Nov 4, 2024
Completion
Dec 31, 2026 (estimated)
Results posted
Dec 4, 2024
Last update
Aug 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion